DAH

3,4-DIHYDROXYPHENYLALANINE

Find entries where: DAH

is present as a standalone ligand in 6 entries

is present in a polymer sequence 21 entries

Find related ligands:

Chemical Component Summary
Name	3,4-DIHYDROXYPHENYLALANINE
Synonyms	L-DOPA
Identifiers	(2S)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid
Formula	C₉ H₁₁ N O₄
Molecular Weight	197.19
Type	L-PEPTIDE LINKING
Isomeric SMILES	c1cc(c(cc1C[C@@H](C(=O)O)N)O)O
InChI	InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
InChIKey	WTDRDQBEARUVNC-LURJTMIESA-N

Chemical Details
Formal Charge	0
Atom Count	25
Chiral Atom Count	1
Bond Count	25
Aromatic Bond Count	6

Drug Info: DrugBank

DrugBank ID	DB01235
Name	Levodopa
Groups	approved
Description	Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
Synonyms	β-(3,4-dihydroxyphenyl)-L-alanine L-DOPA 3,4-Dihydroxy-L-phenylalanine 3-Hydroxy-L-tyrosine (−)-dopa Dihydroxy-L-phenylalanine Levodopum L-beta-(3,4-Dihydroxyphenyl)alanine β-(3,4-dihydroxyphenyl)alanine (−)-3-(3,4-dihydroxyphenyl)-L-alanine L-3,4-dihydroxyphenylalanine Levodopa
Brand Names	Pro-lecarb-100/10 - Tab Rytary Pro-lecarb-100/25 - Tab Stalevo Prolopa Cap 200-50 Aa-levocarb CR Carbidopa and Levodopa Carbidopa, Levodopa, and Entacapone Sandoz Levodopa-carbidopa-entacapone Nu-levocarb - Tab 25 Mg/100 mg Sinemet CR 200/50 Dhivy Apo-levocarb-tab 25mg/100mg Ratio-levodopa/carbidopa Levodopa-carbidopa CR Parcopa Corbilta Sinemet CR 100/25 Carbidopa and levodopa Sinemet 100/10 Duopa Carbidopa, levodopa and entacapone Dom-levo-carbidopa Sinemet CR Inbrija Mint-levocarb Nu-levocarb - Tablets 25 Mg/250 mg Prolopa Cap 50-12.5 Nu-levocarb - Tab 10mg/100mg Teva-levocarbidopa Prolopa Cap 100-25 Levodopa/carbidopa/entacapone Orion Carbidopa, Levodopa and Entacapone Numient Duodopa Apo-levocarb - Tab 25mg/250mg Apo-levocarb - Tab 10mg/100mg Levodopa, Carbidopa and Entacapone Tablets Sinemet Pro-levocarb - 100/25
Indication	Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa[FDA Label]. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism following carbon monoxide intoxication or manganese intoxication[F4579].
Categories	Amines Amino Acids Amino Acids, Aromatic Amino Acids, Cyclic Amino Acids, Peptides, and Proteins Anti-Dyskinesia Agents Anti-Parkinson Agents (Dopamine Agonist) Anti-Parkinson Drugs Benzene Derivatives Biogenic Amines Biogenic Monoamines Catecholamines Catechols Central Nervous System Agents Central Nervous System Depressants Dihydroxyphenylalanine Dopa and Dopa Derivatives Dopamine Agents Hypotensive Agents Levodopa, antagonists & inhibitors Nervous System Neurotransmitter Agents Phenols Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
ATC-Code	N04BA03 N04BA01 N04BA02
CAS number	59-92-7

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Dopamine D1 receptor	MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIR...	unknown	agonist
Dopamine D5 receptor	MLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLL...	unknown	agonist
Dopamine D2 receptor	MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF...	unknown	agonist
Dopamine D3 receptor	MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV...	unknown	agonist
Dopamine D4 receptor	MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLA...	unknown	agonist
Aromatic-L-amino-acid decarboxylase	MNASEFRRRGKEMVDYMANYMEGIEGRQVYPDVEPGYLRPLIPAAAPQEP...	unknown	substrate
Serum albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
Solute carrier family 15 member 1	MGMSKSHSFFGYPLSIFFIVVNEFCERFSYYGMRAILILYFTNFISWDDN...	unknown	inhibitor
Monocarboxylate transporter 10	MVLSQEEPDSARGTSEAQPLGPAPTGAAPPPGPGPSDSPEAAVEKVEVEL...	unknown	inhibitor
Large neutral amino acids transporter small subunit 1	MAGAGPKRRALAAPAAEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNI...	unknown
Large neutral amino acids transporter small subunit 2	MEEGARHRNNTEKKHPGGGESDASPEAGSGGGGVALKKEIGLVSACGIIV...	unknown
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682